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Abstract
Arachidonic  acid  (AA)  metabolites  have  an  important  role  in  mediating  vascular
reactivity to various stimuli, affecting tissue perfusion and tissue supply. In addition,
they exert proinflammatory or anti‐inflammatory effects on vessels. AA is metabolized
by cyclooxygenases (COX) 1 and 2 to prostaglandins (PGs) and thromboxane (TX), by
lipooxygenase  to  leukotrienes;  by  cytochrome  P450  (CYP450)‐hydroxylase  to  20‐
hydroxyeicosatetraenoic acid (20‐HETE) and by CYP450‐epoxygenase to epoxyeicosa‐
trienoic acids (EETs). Increased vascular oxidative stress may induce non‐enzymatic
production of isoprostanes from AA, which, together with vasoconstrictor metabolites
of AA underlie endothelial damage and impaired vascular function. The balance among
vasodilator and vasoconstrictor metabolites of AA may be disturbed in cardiometabolic
diseases.  (e.g.  hypertension,obesity,diabetes)  Dietary  habits  significantly  affect  the
metabolism  of  AA,  particularly  excessive  kitchen  salt  (NaCl)  intake.  Control  of
environmental risks factors, good maintenance of the occurring diseases and balanced
nutrition with restricted salt intake can significantly improve the metabolism of AA and
alleviate microvascular dysfunction and subsequent organ damage. Current research
on pharmacological manipulation of certain components of the AA pathways (such as
20‐HETE  production  inhibition  or  prolongation  of  the  life  of  epoxyeicoatrienoic
acids(EETs) by inhibitors of soluble epoxide hydrolaze (sEH)promises effective therapy
of cardiovascular and cerebrovascular diseases in the future.
Keywords: microcirculation, endothelium, arachidonic acid metabolites, 20‐HETE,
EETs
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1. Arachidonic acid metabolites and their receptors
The polyunsaturated omega‐6 fatty acid 20:4(ω‐6), arachidonic acid (AA), is a major component
of cell membranes which is released from the cell membrane phospholipids primarily by
phospholipase A2 (PLA2). Phospholipases can be activated by stimulation of vascular endothelial
cells with various substances, such as acetylcholine (ACh) or shear stress [1]. AA can be
metabolized by series of enzymes to numerous biological active metabolites termed “eicosa‐
noids” or be transformed by reactive oxygen species (ROS) in nonenzymatic manner into
isoprostanes  [2].  The  endothelium has  a  crucial  role  in  maintenance  of  their  circulatory
homeostasis by producing and releasing different vasoactive substances, which regulate the
tone of the underlying vascular smooth muscle.
Endothelial cells metabolize AA by three enzymatic pathways: cyclooxygenase (COX),
lipoxygenase (LOX), or cytochrome P450 (CYP450) pathway, presented in Figure 1.
Figure 1. Metabolism of arachidonic acid. COX, cyclooxygenase; CYP 450, cytochrome P450; EETs, epoxyeicosatrienoic
acid; LOX, lipoxygenase; PGs, prostaglandins; ROS, reactive oxygen species; TXA2, thromboxane A2; 20‐HETE, 20‐hy‐
droxyeicosatetraenoic acid.
2. COX pathway
The released AA can be metabolized by COXs into prostanoids, which comprise prostaglan‐
dins (PGs) and thromboxanes (TXs). COXs convert AA into endoperoxides (PGH2), the
intermediate of the prostanoid biosynthesis, which can either act as an endothelium‐derived
contracting factor (EDCF) per se, or be further transformed into prostaglandin PGI2 (prosta‐
cyclin) by prostacyclin synthase, or TXA2 by thromboxane synthase. It could also be trans‐
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formed to various other prostaglandins, including PGD2, PGE2, and PGF2α [3]. There are two
isoforms of COXs, COX‐1 and COX‐2, both expressed in physiological and pathological
conditions, but their roles, levels of activation, and affinity to AA could be different [2, 4]. In
most tissues, COX‐1 is constitutively expressed and generates dilator prostaglandins, whereas
COX‐2 is believed to be primarily an inducible enzyme, activated by pro‐inflammatory
conditions [2–5]. Oxidative stress can also serve as an initiator of increased COX‐2 activity [6].
Numerous studies emphasize the importance of COX‐derived metabolites in vascular
reactivity regulation: PGs and TXA2 have a key role in vascular tone expression in both
physiological and pathophysiological conditions [2, 7, 8]. The endothelium is the primary
source of increased COX activity since endothelial cells contain up to 20 times more COX than
vascular smooth muscle cells (VSMC) [9].
3. Prostaglandins and their receptors
Prostanoid receptors, based on their action and signal transduction, can be grouped into three
categories: the contractile receptors, the dilatory receptors, and the inhibitory receptors.
Prostaglandins and their receptors are presented in Table 1 [10–13]. The contractile receptors
(thromboxane‐prostanoid, TP; prostaglandin F, FP; and prostaglandin E1, EP1 receptors)
mediate Ca2+ mobilization and induce smooth muscle contraction. The relaxant receptors
(prostacyclin receptor, IP; prostaglandin D2, DP; prostaglandin E2, EP2; and prostaglandin E4,
EP4) mediate increases in cAMP and induce smooth muscle relaxation. The EP3 receptor is an
inhibitory receptor that mediates decreases in cAMP and inhibits smooth muscle relaxation
[14]. Vasodilatory PGs, including PGI2, PGE2, and PGD2 have an important role in regulating
renal function; they increase renal blood flow and glomerular filtration rate. PGE2 is a key
regulator of sodium reabsorption in the distal tubules [15]. Therefore, these COX‐mediated
factors are crucial in the pathogenesis of cardiovascular and kidney diseases.
Prostaglandin I2 (PGI2) binds to the prostacyclin receptors (IP) that are located on platelets and
vascular smooth muscle cells and mediate inhibition of platelet aggregation and smooth
muscle cells relaxation, thus reducing the risk of thrombosis [2, 16, 17]. PGI2 may represent a
compensatory mechanism of vasodilation when the production of nitric oxide (NO) is
reduced [18].
The expression of IP receptors was observed by in situ hybridization in various mouse organs
showing expression in brain (indicating that IP may be involved in the mediation of pain), in
megakaryocytes and the smooth muscles of arteries (consistent with the action of PGI2 in the
cardiovascular system), in afferent arterioles of the glomerulus (indicating its role in regulation
of the glomerular filtration rate), and in the thymus and spleen (expressed in mature thymo‐
cytes and splenic lymphocytes) [19]. Interaction of PGI2 with IP receptor plays a central
nociceptive role in inflammation. Mice lacking the IP receptor display altered pain perception
as well as inflammatory response [20].
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AA
metabolite 
Receptor  Location  Function in health and in the disease
TxA2 TP‐G protein
coupled
receptor
TPα Lung, spleen, uterus,
placenta, aorta, heart,
intestine, liver, eye,
thymus,
kidney, spinal cord,
brain
Thrombosis/hemostasis, modulation of the
immune response—acute myocardial
infarction, inflammatory lung disease,
hypertension, nephrotic disease
TPβ Human endothelium
PGD2 DP1 Blood platelets,
VSMC and nervous
tissue, including the
central nervous
system,
gastrointestinal SM,
uterine SM
Inhibition of platelet aggregation, SM
relaxation, possibly inhibition of autonomic
neurotransmitter release
DP2
PGE2 EP1 Human
myometrium, kidney,
lung
Contraction and relaxation of SM, inhibition
and enhancement of neurotransmitter
release, inhibition of lipolysis, gastric acid
secretion, inflammatory mediator release, Ig
expression, immunoregulation, inhibition,
and enhancement of nonacid (water)
secretion—inflammation, allergy, parturition,
and tumorigenesis (colon cancer), endometriosis
EP2 SM, ileum, thymus,
lung, spleen, heart,
and uterus
EP3 SM of
gastrointestinal,
uterine, and vascular
origin, gastric
mucosa kidney,
thymus, spleen, lung,
and brain
EP4 SM, endothelium,
endometrium
PGF2α PGF (FP)‐G
protein
coupled
receptor—the
F prostanoid
receptor
FPA Ovary, myometrium,
ocular vasculature, iris
sphincter, ocular
circular muscles
Renal distal
convoluted tubule,
cortical collecting duct,
juxtaglomerular
apparatus
Luteolysis, parturition, uterine contraction,
aqueous humor homeostasis, water, and
electrolyte reabsorption
Renin secretion, blood pressure regulation—
pregnancy‐induced hypertension, pulmonary
and myocardial fibrosis, arrhythmias, myocyte
hypertrophy, VSMC hypertrophy,
vasoconstriction, atherosclerosis
FPB
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AA
metabolite 
Receptor  Location  Function in health and in the disease
Lung and cardiac
fibroblasts;
cardiomyocyte, VSMC
PGI2 IP IP1 Blood platelets, VSMC,
sensory afferent
nerves, thymus
(medulla), spleen,
heart/aorta, lung
Local control of vascular tone, platelet
aggregation—hypertensionIP2
TXA2, thromboxane A2; TP, thromboxane receptor; PGD2, prostaglandin D2; DP, prostaglandin D2 receptor; PGE2,
prostaglandin E2; EP, prostaglandin E2 receptor; PGF2α, prostaglandin F2alpha; FP, prostaglandin F receptor; PGI2,
prostacyclin; IP, prostacyclin receptor.
Table 1. Eicosanoids and their receptors.
The distribution of EP1 receptors is restricted to kidney, lung, and stomach. In kidney, they are
mainly expressed in collecting duct and can be detected in glomerular mesangial cells,
podocytes, and proximal tubule cells. The relationship between EP receptor and blood
pressure (BP), indicated by Stock et al. [21] in EP1 null mice, results from the observed increased
concentrations of renin and aldosterone, ongoing activation of the renin‐angiotensin system
(RAS) and disrupted response to angiotensin II [22].
The EP2 receptors can be found in vascular and interstitial compartments of the kidney and
they are the least abundant among the EP receptors but effectively activate in response to
stimuli. PGE2 evokes contractile and/or relaxant responses of vascular smooth muscles in vitro.
Lack of EP2 receptor and dysfunction of PGE2 pathway may be involved in elicitation of the
salt‐sensitive hypertension in EPP/2 mice (mice lacking EP2 receptor). Their results indicate
that PGE2, produced in the body in response to a high‐salt (HS) diet, evoked considerable
hypertension. It is proposed that the absence of the EP2 receptor abolishes the ability of the
mouse vasculature to vasodilate in response to PGE2 and unmasks the contractile response via
the vasoconstrictor EP receptor(s). EP2 receptors and EP4 can also be found in endometrium.
The amount and localization of these receptors change during pregnancy, which may corre‐
spond to changes in uterine contraction during fertilization and implantation [14].
EP3 receptors are expressed in smooth muscle layer and kidney. Renal EP3 is mostly recognized
for its pressor effects and its diuretic role opposing vasopressin. It is highly expressed in the
distal nephron (mostly in the cortical and medullary collecting duct) [23].
DP is the least expressed receptor found in very low levels in small intestine and brain in
humans [24] and moderately expressed in the ileum, lung, stomach, brain, and uterus [25] in
mice. FP receptors are mainly expressed in corpus luteum and found to be variable during the
estrous cycle indicating a close relationship between FP gene expression and luteolysis.
PGF2α is a physiological inducer of luteolysis in pregnancy. Independent of estrous cycle,
expression of mouse FP mRNA was found in the kidney, heart, lung, and stomach [26, 27].
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Thromboxane A2 (TXA2) is a potent vasoconstrictor and a pro‐aggregatory substance. The
balance between PGI2 and TXA2 in the circulation is important for cardiovascular homeostasis
[17]. TXA2 binds to the thromboxane‐prostanoid (TP) receptors which are located on platelets
and their activation causes platelet aggregation, while in vascular smooth muscle cells, TXA2
causes vasoconstriction and smooth muscle cells proliferation [4, 5].TP receptors appear to be
solely responsible for endothelium‐dependent contractions. Endoperoxides (PGH2) and
higher concentrations of prostacyclin (in vascular smooth muscle lacking IP receptor sensitiv‐
ity) and isoprostanes activate this receptor with a varying range of potency. Role of TP receptors
in hypertensive process was shown by Tian et al. on renovascular hypertensive (RVH) rats.
They showed that TP receptor hyperresponsiveness to vasoconstrictors and IP receptor
insensitivity leads to endothelial dysfunction [6].
4. LOX pathway
The LOX pathways (5, 12, and 15‐LOX) of AA metabolism generates eicosanoids (hydroxyei‐
cosatetraenoic acids, HETEs: 12 (S)‐HETE, 12 (R)‐HETE, and 15 (S)‐HETE), lipoxins (LXs), and
leukotrienes (LTA4, LTB4, LTC4, LTD4, and LTE4) [28]. All of these metabolites have crucial role
in pulmonary responses to asthma, inflammation, and atherosclerosis [29–31]. 5‐LOX products
have been found to be harmful factors in pathological conditions, including cardiovascular
and renal diseases [32]. Leukotrienes produced by 12‐LOX and 15‐LOX cause dilatation, while
the 5‐LOX generated leukotrienes (LTs), the major LO metabolites associated with vasocon‐
striction, increased pro‐inflammatory cytokines production and also behave as chemotaxins
in the blood vessels by recruiting inflammatory cells. LTs are established mediators of pulmo‐
nary inflammation and in allergic and pseudoallergic reactions [33] also known as slow‐
reacting substances of anaphylaxy (SRS‐A) which can be produced in basophils and mast cells.
Research over the past two decades has established that LTs modulate inflammation in
pulmonary arterial hypertension (PAH) [34]. Since LOX pathway does not have much
influence on the peripheral vascular function, and pulmonary circulation and pulmonary
hypertension are not in the focus of this chapter, the further effects of LOX pathway of AA
metabolism will not be discussed here. For comprehensive reading, one may explore many
interesting papers, including [35–37].
5. CYP450 pathway
In addition to COX and LOX, CYP450 enzymes (with their numerous isoforms) represent a
crucial path in AA metabolism, catalyzing epoxidation reactions (producing EETs) and omega
(ω)‐hydroxylation reactions (producing 20‐HETE) [38]. Two distinct enzymes: CYP‐hydroxy‐
lase enzymes (CYP4A and CYP4F) generate HETEs (16‐, 17‐, 18‐, 19‐, and 20‐HETE) while CYP‐
epoxygenase enzymes generate EETs (5,6‐, 8,9‐, 11,12‐, and 14,15‐EET). The CYP epoxygenases,
members of CYP2C (predominant in mammals) and CYP2J classes of enzymatic proteins, are
primarily located in endoplasmic reticulum of endothelial cells. They convert AA to EETs by
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adding an epoxide across one of the four double bonds in AA and produce the four mentioned
EET regioisomers. CYP epoxygenases demonstrate a very high sequence homology among
different species (e.g. human CYP2C8, rat CYP2C23 and mouse CYP2c44) [39–41]. Beside
CYP2C8, human arteries and arterioles express CYP2C9, CYP2J2, and soluble epoxide
hydrolases (sEH) enzymes [42, 43]. sEH converts EETs to their corresponding diols, dihydrox-
yeicosatrienoic acids (DHETs), which represent the main EET catabolic pathway. EETs
produced by the endothelium hyperpolarize vascular smooth muscle cells VSMCs by open-
ing Ca2+-activated K+ (KCa) channels leading to vasodilatation. In contrary, 20-HETE is found
to be a vasoconstrictor that inhibits the opening of KCa.
Key vascular effects of CYP epoxygenase-derived EETs, besides regulating vascular tone and
angiogenesis, include autocrine anti-inflammatory actions, limitation of leukocyte adhesion
and reducing VSMCs proliferation. They have been found to exhibit protective effects in
myocardial and cerebral ischemia and in hypertension-induced renal damage [44].
EETs are also able to modulate vascular responses to other stimuli, such as hormonal and
paracrine agents. For instance, vasopressin-induced increase in cytosolic Ca2+ in renal mesan-
gial cells is amplified by EETs and reduced when EETs synthesis is inhibited [45]. The responses
of afferent arterioles to angiotensin II, endothelin-1, and noradrenaline increase when EETs
synthesis is inhibited [45]. In transgenic rats with angiotensin II-dependent hypertension, EETs
were shown to be antihypertensive and cardioprotective [46]. Inhibition of EETs synthesis
reduces glutamate-induced increase in cerebral blood flow response [47]. Streptozocin-
induced diabetes in rats (a model for type 1 diabetes mellitus, DM) reduces the levels of
protective EETs, and reduced EETs levels lead to exacerbation of stroke [48]. A similar
protective role of EETs was demonstrated in diabetic nephropathy [49], atherosclerosis [50],
and cardiac ischemic reperfusion injury in diabetic rats [51]. Reduced CYP activity and EETs
production caused by high glucose (through elevated superoxide levels) in coronary endo-
thelial cells has also been implicated in impaired endothelium-dependent vasodilation of
coronary arterioles [52]. EETs might constitute a key link between insulin resistance and
endothelial dysfunction [53]. Upregulation of the CYP2J group of isoforms in mice (which
catalyze EETs formation) leads to attenuation of diabetic nephropathy induced by streptozo-
cin [54].
Both EETs and HETE exert numerous biological signaling effects, including important roles in
the vasculature, vessel diameter regulation, and tissue perfusion. EETs function as endotheli-
um-derived hyperpolarizing factor and show mostly vasodilator properties, with their
vasodilator effects comparable to that of ACh [46], but some EET subtypes can also mediate
vasoconstriction—for example, in kidneys where they can cause constriction of the afferent
arterioles [46, 55]. 20-HETE is a potent vasoconstrictor and plays an essential role in the
myogenic and tubuloglomerular feedback responses in the afferent arteriole, participating in
blood pressure control [56].
Many evidences suggest that alteration in EET pathway contributes to the pathophysiology of
hypertension, including BP elevation, endothelial dysfunction, and end-organ damage [44].
Also, EETs have anti-inflammatory and angiogenic function [32]. Imbalance of vasoactive
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eicosanoids leads to ischemia, thrombosis, coagulopathy, myocardial infarction, and stroke as
discussed further in the chapter.
6. Nonenzymatic metabolism of AA
ROS are produced in all layers of the vascular wall by all vascular cell types (endothelium,
smooth muscle, and adventitial cells) and by perivascular adipocytes. ROS generated by
endothelial cells are superoxide (O2·), hydrogen peroxide (H2O2), hydroxyl radicals (HO), and
others. Potential sources of endothelial ROS generation include mitochondria, xanthine
oxidase (XO), uncoupled NO synthases (NOS), lipoxygenases, cytochrome P450 enzymes, and
nicotinamide adenine dinucleotide phosphate (NAD(P)H) oxidases [57]. ROS are formed on
sites of inflammation and injury; at low concentrations, ROS can act as a signaling molecule
involved in the regulation of fundamental cellular activities such as cell growth and cell
adjustments and regulation of endothelial function, while at higher concentrations, ROS can
cause cell injury and death. Increased concentration of ROS is associated with changes in
endothelial signal transmission and redox‐regulated transcription factors in inflammation
which may be related to endothelial dysfunction and activation of pathological mechanisms
[58]; for example, the development of hypertension. This includes promoting the growth of
VSMCs, increased contractility and invasion of monocytes and inflammation, increased
permeability of vascular endothelium and enhanced adhesion of leukocytes [58].
ROS can induce peroxidation of AA, which gives rise to the isoprostanes. Several scavenger
systems are counteracting the ROS, including enzymes such as superoxide dismutase (SOD),
catalase (CAT) and glutathione peroxidase (GPx), and nonenzymatic antioxidants such as
vitamin E, vitamin C, β‐carotene, and heme‐binding proteins, and major of them is SOD [59].
ROS can directly act as endothelium‐derived contracting factor (EDCF) [60] or indirectly
potentiate EDCF‐mediated responses by reducing the bioavailability of NO [61] and activating
COX in the VSMCs [3]. Their overproduction leads to increased oxidative stress and develop‐
ment of endothelial dysfunction [62]. Thus, endothelial dysfunction impairs vascular function
in various diseases, cardiovascular and endocrine‐metabolic disorders. Oxidative stress is
characterized by reduced bioavailability of NO and enhanced production of ROS [63] which
can exhibit both activating and inhibitory effects on the eicosanoid metabolism, and PGI2
synthesis is more sensitive then TX and LOX pathways. In blood vessel, production of PGI2 is
selectively inhibited by ROS, whereas TXA2 synthase is unaffected [64]. ROS can modify
vascular tone directly by acting as EDCF or indirectly by reducing the bioavailability of NO
which potentiate EDCF‐mediated responses.
Urinary isoprostane levels are used as biomarkers of oxidative stress in ischemic‐reperfusion
injury, atherosclerosis, and hepatic disease. An accumulated body of evidence suggests that
there is a cross‐talk between 20‐HETE and ROS production in response to flow‐ and pressure‐
induced stimuli in human and experimental animal microcirculation [65, 66]. Novel data show
an association between increased CYP4A activity and oxidative stress in human subjects with
hypertension. Increased urinary 20‐HETE excretion correlated positively with markers of
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oxidative stress and with elevated BP [67]. Similarly, patients recovering from acute ischemic
stroke have increased plasma 20‐HETE concentrations and elevated plasma oxidative stress
markers compared to healthy controls [68].
7. Endothelial dysfunction and metabolites of arachidonic acid
Eicosanoids play an important role in maintenance of vascular reactivity under physiological
conditions, but they become deleterious to endothelial function and BP regulation in some
conditions with imbalance in the PGI2/TXA2 system, in chronic activation of CYP4A and
enhanced production of 20‐HETE or lack of EETs, as well as in high oxidative stress conditions.
At the beginning of the endothelial dysfunction development, there is a compensatory
endothelial mechanism of prostacyclin and/or endothelium‐derived hyperpolarizing factor
(EDHF), which maintains vascular function (Figure 2).
Figure 2. The role of AA metabolites’ disbalance in endothelial dysfunction. EETs, epoxyeicosatrienoic acid; PGI2,
prostacyclin; ROS, reactive oxygen species; TXA2, thromboxane A2; 20‐HETE, 20‐hydroxyeicosatetraenoic acid.
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Except reduced NO bioavailability and increased ROS production, in some pathological
conditions such as hypertension, diabetes, and obesity, there is an overproduction of COX‐2‐
derived prostanoids. Endothelial dysfunction is a hallmark of most cardiovascular and
endocrine/metabolic diseases.
8. Obesity
Obesity is associated with microvascular endothelial dysfunction in experimental animal
models as well as in obese humans [69, 70]. Human studies have shown that endothelial
function of visceral adipose tissue vessels is more damaged compared to subcutaneous adipose
tissue vessels [70, 71], and that visceral microenvironment is intrinsically more toxic to the
vasculature. Also, COX‐derived vasoconstrictors partly contribute to endothelial dysfunction
[71, 72]. There is a large body of evidence that endothelial dysfunction precedes and predicts
clinical disease [73, 74], suggesting that endothelial dysfunction and impaired vascular
reactivity is an initial step in the development of cardiovascular complications caused by
obesity. Therefore, endothelial dysfunction in adipose tissue may be a strong prognostic factor
for future cardiovascular events [75].
In obesity, chronic exposure of endothelial cells to high levels of circulating fatty acids increases
the formation of ROS, which further leads to a disbalance between vasodilation and vasocon‐
striction leading to net vasoconstriction. Vascular production of PGs can be also altered in
obesity because endothelial production of the superoxide anion contributes to enhanced COX
expression [76].
Vasodilation in response to flow is reduced in visceral compared to subcutaneous arterioles,
and the COX metabolites have been shown to participate in the mechanisms of endothelium‐
dependent dilation in subcutaneous adipose tissue resistance arteries [70, 71]. Furthermore,
ROS (mainly H2O2) participate in that response, while the metabolites of the CYP450 partially
contribute to dilation of microvessels from both subcutaneous and visceral adipose tissues [70].
In pathological conditions, such as cardiovascular disease and obesity, NO bioavailability is
reduced and other endothelium‐derived dilator substances compensate for the lack of NO
release during flow or agonist activation [70, 77]. The inhibition of NOS augments the contri‐
bution of CYP450 metabolites to vasodilation [78], suggesting that EDHF may function as a
compensatory mechanism when NO synthesis is impaired in obesity. It is also possible that
CYP450 metabolites and COX enzymes are sources of ROS [79], whose production is enhanced
in obesity and cardiovascular disease [70, 77].
Taken together, data suggest that endothelium‐derived dilator substances other than NO (i.e.
H2O2 and metabolites of CYP450) may contribute to vasodilation in obesity [70]. Previous
studies in the coronary circulation have shown that the P450 component to dilation is present
during coronary disease when NO levels are reduced [80]. Therefore, it is possible that the
P450 component to dilation in adipose tissue is conserved during disease in the presence and
the absence of NO‐dependent vasodilation.
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9. Arachidonic acid metabolites and hypertension
High BP represents a major risk factor for coronary artery disease, stroke, heart failure,
peripheral vascular disease, vision loss, and chronic kidney disease [81, 82]. Reduced releasing
of NO and enhanced production of EDCF increase contraction and lead to vascular diseases
such as hypertension [83]. Chronically increased arterial BP presumably can cause premature
aging of the intima, arterial remodeling, and smooth muscle cells dysfunction. Proper func‐
tioning of the endothelium and delayed appearance of vascular complications caused by
hypertensive process can be managed by increasing the availability of NO, favoring the EDHF‐
mediated responses, and preventing the release or action of EDCFs.
Ever since the 1990s when the COX‐pathway‐independent EDHFs were discovered, substan‐
tial number of studies demonstrated CYP450 metabolites of AA to be that other source and
these newly discovered EDHFs (EETs and HETEs) were proven to have influence in patho‐
physiology of many diseases including hypertension. Production of vasoconstrictor cycloox‐
ygenase products, especially ROS, contributes to the development of endothelial dysfunction
in hypertension [84, 85]. Until today, wide array of techniques and different types of blood
vessels have been comprehensively investigated to discover EET‐mediated VSMC signaling
mechanisms. Prevailing conclusion of these studies is that EETs activate K+ channels in vascular
smooth muscle cell and in particular the large‐conductance KCa channels causing cell mem‐
brane hyperpolarization [86–88]. Another consistent finding has been increase in cAMP in
response to EETs, and this signaling pathway has been associated with vasodilation [86–88].
To achieve vasorelaxations, EETs and other EDHFs also require a guanine nucleotide binding
protein (protein G) [89, 90]. Capdevila and Falck showed in their study that the EDHF‐
mediated response (therefore EETs) becomes evident only in the state of reduced NO bioa‐
vailability meaning that physiological concentration of NO is adequate to moderate EDHF
generation and, under physiological conditions, endothelium‐dependent vasodilatation seems
to be mainly dependent on NO production [91]. EETs are also contributing to shear stress‐
dependent hyperpolarization and dilation of skeletal muscle arterioles in mice [92–94]. eNOS‐
deficient mice have had intact vasorelaxation to shear stress and a reduced vasodilation to ACh
also suggesting that EETs can possibly enlarge their contribution to attenuate vascular
resistance when NO levels are reduced demonstrating inhibitory interaction between NO and
EETs [95]. Another study on essential hypertensive patients showed also connection between
impaired NO availability and alternative mechanism of endothelium‐dependent vasodilata‐
tion, related mainly to compensatory CYP2C9‐derived EDHF [96]. Experimental findings in
humans have also determined that NO and CYP epoxygenases regulate arterial stiffness in
response to flow variations [97]. Early observation on the possible contribution of EETs to BP
control and hypertension came from studies on rats treated with an epoxygenase enzyme
inhibitor who became hypertensive when fed high salt [98–100]. Study in transgenic mice
which expressed human CYP2J2 and CYP2C8 epoxygenases in endothelium and increased
endothelial EET biosynthesis has proved that endothelial CYP epoxygenases regulate BP [101].
In fact, these mice exhibit enhanced afferent arteriolar dilation, lower BP, and attenuated
hypertension‐induced renal injury compared to wild type [101]. These findings suggest the
potential therapeutic utility of antihypertensive strategies that may increase CYP‐derived
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EETs. Recently, a protective role of CYP2J2‐derived EETs was found in heart failure [102],
suggesting that CYP2J2‐derived EETs may be a target for the development of drugs to prevent
cardiac hypertrophy and cardiomyocyte apoptosis in heart failure [44]. Sinal et al. showed that
mice lacking the sEH gene (epoxide hydrolase 2, Ephx2‐/‐) have significantly higher circulating
EET levels and lower BP compared to wild‐type mice. Renal production of DHETs was
decreased and EET formation increased in the Ephx2‐/‐mice, also suggesting an important role
for epoxygenase metabolism in the regulation of BP [103]. In addition, the administration of a
sEH inhibitor (sEHI) significantly lowers BP in various rodent models of hypertension [103,
104]. The administration of a single dose of an sEHI (N,N‐dicyclohexylurea, DCU) to ANG II‐
infused rats greatly increased the level of EETs, decreased the urinary DHET excretion, and
lowered systolic BP, thus reversing the hypertensive phenotype typical of the spontaneously
hypertensive rats (SHR) [105, 106]. However, adverse events may occur in the pulmonary
vasculature. EETs, generated in VSMCs of pulmonary blood vessels, increase intracellular
Ca2+, thus inducing vasoconstriction and increasing pulmonary artery pressure [107].
10. Role of 20‐HETE in hypertension
20‐HETE is a CYP450–derived omega‐hydroxylation metabolite of arachidonic acid and plays
a complex role in blood pressure regulation. 20‐HETE biosynthesis is primarily localized to
the VSMCs [108], with the exception of endothelium in the pulmonary circulation which may
also produce 20‐HETE [109]. In physiological conditions, NO, carbon monoxide (CO) and
superoxide inhibit the formation of 20‐HETE by binding to the heme binding site of the CYP450
pathway enzymes. A role of 20‐HETE in NO homeostasis was first suggested by Frisbee et al
[110]. They showed that 20‐HETE decreases the effect of ACh‐induced relaxation in cremasteric
arterioles. Studies using endothelial cells demonstrated that 20‐HETE stimulates superoxide
production by mechanisms that include eNOS uncoupling and activation of NAD(P)H
oxidase‐dependent and ‐independent pathways [110–113]. The rate of 20‐HETE biosynthesis
is inversely proportional to the blood vessel diameter [114]. 20‐HETE is not detected in large
conduit vessels [115].Therefore, it is largely believed that 20‐HETE is an eicosanoid of the
microcirculation [116]. In the microvasculature, 20‐HETE has been shown to play a pressor
role by sensitizing VSMCs to constrictor stimuli and increasing myogenic tone and by acting
on the endothelium to further promote endothelial dysfunction and endothelial activation
[116].While the formation of 20‐HETE in VSMC is stimulated by angiotensin II and endothelin
and is inhibited by NO CO, inhibition of 20‐HETE synthesis attenuates the vascular responses
to angiotensin II, endothelin, noradrenaline, NO, and CO [115]. Other autacoids can also
stimulate 20‐HETE production, for example, serotonin (5‐hydroxytryptamine, 5‐HT], and
other growth factors [117, 118]. Liu et al. showed that inhibitors of COX‐2 increase the levels
of 20‐HETE [119]. The report by Sacerdoti et al. [120] was the first to implicate 20‐HETE in the
pathogenesis of hypertension showing that depletion of renal CYP450 normalizes BP in SHR
rats. ANG II‐mediated hypertension in rats can be decreased by 40% by inhibition of 20‐HETE
synthesis [116]. Contribution of 20‐HETE to blood pressure regulation include diet‐, age‐, and
sex‐specific alterations in the expression of CYP enzymes that produce 20‐HETE [121]. In
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pregnancy‐induced hypertensive women, the urinary excretion of DHETs is increased
compared to healthy pregnant women, which may implicate an increased degradation of
EETs [122].
On the contrary, 20‐HETE is contributing to antihypertensive mechanisms too; it is involved
in the regulation of the pressure‐natriuretic response by inhibitory acting on sodium reab‐
sorption and promoting natriuresis in the kidney tubules [123]. HET0016, which is cytochrome
P450 ω‐hydroxylase inhibitor, attenuates cerebrovascular inflammation, attenuates oxidative
stress, and improves vasomotor function in spontaneously hypertensive rats [124].
RAS is the crucial in regulation of body fluid volume and blood pressure [125]. ANG II
increases blood pressure by (1) vasoconstriction via AT1R activation, increased sympathetic
tone, and the release of arginine‐vasopressin and (2) modulation of renal sodium and water
reabsorption by stimulating renal AT1R, the production and release of aldosterone, or the
sensation of thirst in the central nervous system [116].
ANG II stimulates 20‐HETE synthesis in renal microvessels and decreases EET levels by
downregulating epoxygenases and increasing their degradation by increasing expression and
activity of sEH [117, 126, 127]. In conditions, such as renovascular disease (RVD), there is an
increase in the expression of the renin‐angiotensin system, associated with enhanced lipid
peroxidation related to activation of the renin‐angiotensin system [125], elevated levels of ANG
II, which parallels an increase in plasma 20‐HETE and a decrease in EET plasma levels that
supports a pivotal role of EETs in vascular homeostasis [125]. RVD is a relatively rare form of
secondary hypertension [128, 129]. The interactions between 20‐HETE and the RAS occur at
several levels. Increased production of 20‐HETE in the peripheral vasculature contributes to
the acute vasoconstrictor response to ANG II, whereas acute and chronic inhibition of 20‐HETE
synthesis attenuates the renal pressor response to ANG II and the development of ANG II‐
dependent hypertension [116], respectively. The infusion of angiotensin II (ANG II), a potent
vessel constrictor, elevates blood pressure in various animal models [106].
In RVD, plasma 20‐HETE significantly correlated with plasma renin activity, thus suggesting
its role in the elevation of blood pressure through the possible increase of vasomotion and
vascular reactivity [130]. All of presented studies suggest that there is a communication
network among various eicosanoids. In physiological conditions, eicosanoids are important
in the maintenance of vascular tone and reactivity, but in chronic activation of CYP4A/20HETE
system or lack of EETs and high oxidative stress, they become deleterious to endothelial
function and blood pressure regulation.
11. Arachidonic acid metabolites and high‐salt diet
It is well known that increased NaCl intake is an important risk factor for development and
progression of hypertension [131, 132], while a reduction in dietary sodium is associated with
lowering of BP in many patients with essential hypertension [133]. Furthermore, some studies
on normotensive animal models have shown that changes in NaCl intake determined vascular
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responses to various physiological stimuli, in conduit vessels and resistance arteries, as well
as in the microcirculation [134–136].
In contrast to studies which demonstrated deleterious effects of high levels of ANG II and RAS
activation on the BP levels [125], there are studies demonstrating that decrease in ANG II
circulating levels leads to impaired microvascular endothelial function. This has been recently
extensively reported in the paper by Boegehold et al. [137]. One of the most deleterious effects
of HS intake is impaired endothelial function [132], and it is crucial to evaluate the altered
vascular function in microcirculation because it is a target of the pathological events. In animal
models, even a short‐term HS diet impairs vascular function by altering the responses to both
vasoconstrictor and vasodilator stimuli in different vascular beds [134–136], that is associated
with overproduction of vasoconstrictor factors, TXA2, and PGF2α [134, 136].
In their study, Cavka et al. have shown that one week of HS diet increased plasma levels of
potent vasoconstrictor, TXB2, and that the nonselective COX antagonist indomethacin restored
blood flow, whereas the selective COX‐2 inhibitor did not cause any change in the impaired
hyperemic blood flow in healthy young women [138]. Further, both inhibitors reduce plasma
TXA2 levels, suggesting that some other vasoconstrictor dominantly derived by COX‐1 may
play important role in impaired microvascular reactivity in subjects on the HS diet. Short‐term
exposure to a HS diet alter AA metabolism, and COX enzymes (mainly COX‐1) play an
important role in the development of microvascular endothelial dysfunction [138].
As already mentioned, in vascular pathogenesis, there may be a disbalance where COX‐
derived constrictors become dominant over the prostacyclin which is usually responsible for
vasodilatation under physiological conditions [3, 139]. In endothelial dysfunction, endothelial
cells became a source of COX‐derived constrictors and enhanced oxidative stress may modify
COX‐dependent function leading to damaged vascular tone [9] due to decreased NO bioa‐
vailability and an increased formation of EDCFs [140]. In animal models, COX‐1 metabolites
are responsible for endothelium‐dependent contractions, but with aging or disease, COX‐2 can
be induced contributing to EDCF‐mediated responses [140, 141].
HS‐induced endothelial dysfunction is caused by decreased plasma concentration of ANG II
which leads to increased oxidative stress [139, 142, 143], as demonstrated in SS.BN13 consomic
rats studies [139], leading to impaired relaxation of middle cerebral artery (MCA) in response
to hypoxia and ACh due to decrease in vascular antioxidative capacity [144]. Importance of
ANG II is further supported by intravenous infusion of suppressor dose of ANG II during HS
diet which restores normal vascular relaxation and restores ROS concentration to normal
values [145].
Antioxidative systems are very important in the maintenance of cellular redox homeostasis
and prevent excessive accumulation of O2‐· and its reactive metabolites [146]. Reduced activity
of antioxidant mechanism, alone or in combination, with increased O2‐ production, may
contribute to increased vascular O2‐· level associated with a high intake of salt [144]. Several
ubiquitous primary antioxidant enzymes such as SOD, catalase, and peroxidase catalyze the
conversion of ROS in more stable molecules such as O2 and water. Until now, research of the
influence of high salt intake was based exclusively on changes in the level of SOD isoforms.
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Lenda et al. presumed that HS diet decreased the protein expression or activity of the antiox‐
idant enzymes (SOD isoforms) leading to increase oxidative stress, and consequently, reduced
dilatation of blood vessels [143, 147]. However, this effect is not uniform at each vascular bed;
for example, HS intake has no effect on the expression of CuZn SOD or MnSOD in mesenteric
arteries [146] or the expression of CuZn SOD in the arteries of skeletal muscle [141]. Studies
on Ren1‐BN congenic rats showed that a short‐term increase in dietary salt intake reduces the
expression of the Cu/Zn SOD and Mn SOD in the cerebral vasculature and that ANG II infusion
prevents the reduction of Cu/Zn SOD expression, but not Mn SOD expression, in HS‐fed
animals [143]. Recent studies showed that, except for reduced protein levels of SOD isoforms,
HS intake also significantly reduced the level of mRNA expression of glutathione peroxidase
4 GPx4, very important enzyme in maintaining reduced levels of lipid peroxidation and
oxidative stress [142]. Treatment with TEMPOL [136, 148] (which is a SOD mimetic) returns
the NO level to the concentrations similar to the ones in the animals on a normal salt diet which
indicates that the O2‐· is responsible for the oxidation of NO under these conditions. HS diet
promotes increased generation of superoxide anion from NOS in spinotrapezius muscle
arterioles of C57BL/6J mice, thus impairing endothelium‐dependent dilation through reduced
NO bioavailability [149].
There are several possible sources of O2‐· in the vascular wall such as mitochondrial respiratory
chain, NAD(P)H xanthine oxidase, COX, CYP‐450 enzyme, and the NOS [150]. When the
bioavailability of NO is greatly reduced, as is the case during HS diet, endothelium activates
various compensatory physiological pathways. Impaired endothelium‐dependent vasodila‐
tion is maintained partially by the production and release of other endothelial vasodilator other
than NO, such as prostanoids (prostacyclin) and other endothelium hyperpolarizing factors
(EDHFs). In endothelial dysfunction, besides ROS, other harmful metabolites of the arterial
wall are formed, that is, TXA2 and PGH2 [151]. Endothelial dysfunction is related to patho‐
genesis of thrombosis and atherosclerosis [151, 152]. mRNA expression of COXs (COX‐1 and
COX‐2) showed a significant reduction of both isoforms in the brain blood vessels after a week
of HS intake [153]. New functional studies demonstrated that the flow‐mediated dilatation in
isolated cerebral arteries of Sprague‐Dawley (SD) rats on a high salt is not mediated by COXs
neither with EETs [154], which is a further evidence of the abovementioned results of the
molecular studies.
Lombard et al. reported that the production of TXA2 and PGI2 was altered by HS diet, TXA2
contributed to impaired vascular response to reduced oxygen partial pressure (PO2) in animals
on HS diet, and that MCA of animals on a HS diet decreased the production of PGI2 in hypoxic
conditions [155].
Taken together, there is a cross‐talk between the enzymes producing the vasoactive metabolites
and ROS—ROS may be the side‐product of impaired activation of COX, NOS, or CYP450
enzymes together with NAD(P)H oxidase activation, and simultaneously, ROS may affect the
production of vasoactive metabolites of COX, shifting the production of them from vasodila‐
tors to vasoconstrictors and affecting the bioavailability of NO [153, 156, 157] (Figure 3).
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Figure 3. Schematic overview of the influence of high salt intake to increased oxidative stress and reduced vasodila‐
tion. Ang II, angiotensin II; CAT, catalase; COXs, cyclooxygenases; CYP 450, cytochrome P450; EETs, epoxyeicosatrie‐
noic acid; GPx 4, glutathione peroxidase 4; NO, nitric oxide; PGI2, prostacyclin; ROS, reactive oxygen species; SOD,
superoxide dismutase; TXA2, thromboxane A2; VSMC, vascular smooth muscle cell; 20‐HETE, 20‐hydroxyeicosatetrae‐
noic acid.
12. Arachidonic acid metabolites and diabetes mellitus
It is clearly recognized that elevated plasma concentration of glucose is responsible for the
pathogenesis of vascular complications associated with DM; hyperglycemia can modify
vascular function—it compromises the endothelium‐dependent relaxation, increases the
contractile response of vascular smooth muscle and the development of inflammatory,
thrombotic, and atherosclerotic events.
Impaired endothelium‐dependent vasodilatation has been shown in various vascular beds of
different animal models and in human with DM [62]. In patients with DM type 2 and in diabetic
mice, reduced production on NO, increased generation of ROS, and enhanced vasoconstrictor
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tone were related to impaired endothelium‐dependent vasodilation [158]. This attenuated
vascular response includes multiple mechanisms, but it seems that increased oxidative stress
is the first alteration that triggers more others. Similar to findings in hypertension and high
salt diet, endothelial dysfunction in diabetes could also be related to the release of vasocon‐
strictor mediators, for example, increased production of 20‐HETE leading to activation of ROS
through an NAD(P)H‐dependent pathway. This may have an important therapeutic potential
in the treatment of diabetic vascular complications, for example, nephropathy [159].
The impaired endothelium‐dependent dilation to ACh in diabetic animals is due to the
accompanying release of EDCF and can be attributed to the exposure of the endothelial cells
to high blood glucose level, causing increased oxidative stress and overexpression of both
COX‐1 and COX‐2 [160]. Also, as previously mentioned in the paragraph on COXs metabolites
and ROS, increased ROS production may determine vasoconstrictor response. Exogenous
administration of AA in diabetic dogs induces TXA2‐mediated contraction, while increases the
prostacyclin‐mediated vasodilation in the arteries of control dogs [161]. ACh‐induced vaso‐
dilation of diabetic aortas, mesenteric arteries, and femoral arteries is reduced, but COX
inhibitors improve that response [162]. Some studies have shown that hyperglycemia increases
the expression of COX‐2, in large blood vessels and in microcirculation, leading to increased
production of vasoconstrictor prostanoids which modify vascular reactivity [162]. Numerous
data indicate that there is an increase the release of ROS from endothelial cells in DM, especially
superoxide anion, which is thought to be particularly responsible for the increased COX‐2
expression [62]. Hyperglycemia increases the release of AA, modifies the formation and
function of prostanoids, and thus induces modification of vasomotor tone [62].
Other enzymes, which metabolize AA, are affected by diabetes. Diabetes alters CYP expression
and 20‐HETE formation, leading to upregulation of CYP4A isoforms and to elevated levels of
20‐HETE [115]. The 20‐HETE inhibitor HET0016 attenuates the development of diabetes‐
induced vascular dysfunction, suggesting a contribution of 20‐HETE to endothelial dysfunc‐
tion in diabetes and other insulin‐resistant conditions [163]. Recent findings also suggest that
20‐HETE impairs insulin‐stimulated vasodilator effects that are mediated by the IRS‐1/
PI3K/AKT/eNOS pathway [163]. Elevated levels of CYP‐derived 20‐HETE in diabetic patients
with cardiac ischemia are associated with dysfunction of circulating endothelial progenitor
cells and angiogenic capacity [164]. On the other hand, experiments have indicated that in
streptozocin‐induced diabetic rats (with impaired endothelial function and contractile
responses), the vascular CYP2E1 is significantly increased, leading indirectly to a reduction in
the levels of the potent vasoconstrictor 20‐HETE (by inhibiting CYP4A enzymes). Preincuba‐
tion of vessels in vitro with 20‐HETE rescued contractile functions, suggesting that the role of
20‐HETE in diabetes‐induced vascular dysfunction is complex, although those experiments
were conducted on aortic vascular models and not in microcirculation [165].
In experiments conducted on two animal models (streptozocin‐treated rats) with different
levels of glucose metabolism impairment—glucose intolerance model and diabetic model, the
expressions of CYP enzymes involved primarily in production of EETs (CYP2J4, CYP2C23)
and HETE(CYP4A2 and CYP4A3) were compared, as well as sEH (which degrades EETs) [166].
In the glucose intolerance model, increased degradation of EETs by elevated expression of
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soluble epoxide hydrolase might contribute to endothelial dysfunction. Findings in the
diabetic model suggest a different mechanism, primarily a shift in the balance between EETs
and 20‐HETE production caused by changes in CYP2J4 and CYP4A3 expression [166–168].
13. Arachidonic acid metabolites and stroke
In recent years, studies suggest that hypertension, a risk factor for stroke, is associated with
an increased production of 20‐HETE in the wall of cerebral vessels [169]; 20‐HETE has a crucial
role in cerebral blood flow regulation [170] and is a well‐described mediator or neural tissue
damage in stroke [169]. 20‐HETE increases the production of ROS [171–174], has a role in
increasing vasospasm following subarachnoid hemorrhage (SAH), and also affects infarct
volume after t‐MCAO in rats. Its inhibitors, such as HET0016 [175], reduce vasospasm after
SAH and reduce stroke volume and neurological outcome after stroke. Dunn et al. showed
that in spontaneously hypertensive rats the CYP4A expression and 20‐HETE production were
raised in the cerebral vasculature and that inhibition of 20‐HETE production noticeably
reduced the infarct size and endothelial dysfunction presented in stroke [169]. In humans,
excretion of 20‐HETE is associated with hypertension and endothelial dysfunction. Ward et al.
showed that plasma concentrations of 20‐HETE, EETs, and DiHETEs were elevated in patients
with acute ischemic stroke and increased oxidative stress was present noticeable by increased
plasma F2‐isoprostanes [68]. It is considered that free radicals formation that accompanies
ischemic brain injury is an acute response [68].
Pretreatment and treatment with 20‐HETE inhibitors have been proposed as a new potential
approach for stroke treatment [176]. Recently, beside 20‐HETE, other metabolites of AA, such
as EETs, have been shown to have a potential to alleviate the impairment of tissue perfusion
and detrimental outcome of stroke [177–179]. Several studies demonstrated that stabilizing the
levels of EETs is important, and that the inhibition of sEH is cerebroprotective against ischemic
stroke and SAH [177, 178]. Thus, CYP metabolites could play an important role as new targets
for the pharmaceutical industry in managing brain damage that occurs with cerebral ischemia
and stroke [180].
14. Conclusion remarks
In conclusion, it is obvious that metabolites of AA play an extremely important role in the
mechanisms of microvascular responses and microvascular regulation of tissue blood flow and
perfusion. Balance between vasodilator and vasoconstrictor metabolites of AA may be
disturbed in various cardiometabolic diseases (such as hypertension, stroke, obesity, diabetes)
and underlies endothelial dysfunction which is related to many complications accompanying
these diseases. Dietary habits significantly affect the metabolism of AA, particularly excessive
NaCl intake or high blood glucose levels lead to endothelial dysfunction, as well. Control of
environmental risks factors, good maintenance of the occurring diseases, and balanced
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nutrition with restricted salt intake can significantly improve metabolism of AA and alleviate
possible microvascular dysfunction and subsequent organ damage. Current research on
alternative pathways of AA metabolism and pharmacological manipulation with certain
components of the AA pathways (such as 20‐HETE production inhibition or prolongation of
the life of EETs by sEH inhibitors) promises effective therapy of cardiovascular and cerebro‐
vascular diseases in the future.
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